biosimilars and infusion systems. Product Categories Legacy Established Products: Legacy established products include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). The company’s major products and its primary indications include Lipitor for reduction of LDL cholesterol; Premarin family for treating symptoms of menopause; Norvasc for the treatment of hypertension; Xalatan/Xalacom Glaucoma and ocular hypertension; Zoloft for depression and certain anxiety disorders; Relpax to treat the symptoms of migraine headache; EpiPen as an epinephrine injection used in treatment of life-threatening allergic reactions; Effexor for depression and certain anxiety disorders; Zithromax/Zmax for bacterial infections; Xanax/Xanax XR for anxiety disorders; Cardura for hypertension/benign prostatic hyperplasia; Neurontin for seizures; Diflucan for fungal infections; Tikosyn for the maintenance of normal sinus rhythm, conversion of atrial fibrillation/flutter; Depo-Provera as a contraceptive; and Unasyn as an injectable antibacterial. Peri-LOE Products: Peri-LOE products primarily include Celebrex for the treatment of arthritis pain and inflammation, and acute pain; Zyvox for bacterial infections and Revatio for pulmonary arterial hypertension in most developed markets, Lyrica in the European Union (EU) for epilepsy, neuropathic pain and generalized anxiety disorder; Pristiq for depression in the U.S.; and Inspra in the EU. Its products also comprise Vfend for treating fungal infections; and Viagra GEP for treating erectile dysfunction. Sterile Injectable Pharmaceuticals: Sterile injectable pharmaceuticals includes generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). It offers Medrol for the treatment of inflammation; Sulperazon as an antibiotic; Fragmin as an anticoagulant; and Tygacil as an antibiotic. Infusion Systems: Infusion systems includes medication management systems products composed of infusion pumps and related software and services, as well as I.V. infusion products, including large volume I.V. solutions and their associated administration sets. Biosimilars: Biosimilars includes Inflectra (biosimilar infliximab) in Canada, Mexico, Australia and certain European markets, Nivestim (biosimilar filgrastim) in Australia and certain European and Asian markets and Retacrit (biosimilar epoetin) in certain European markets. Other Established Products: Other established products includes legacy Hospira, Inc. one-to-one contract manufacturing and bulk pharmaceutical chemical sales organizations. Hospira, Inc. provides sterile injectable drugs and infusion technologies, as well as a provider of biosimilars. Marketing In the company’s global biopharmaceutical businesses, the company promotes its products to healthcare providers and patients. Through its marketing organizations, the company explains the approved uses, benefits, and risks of its products to healthcare providers, such as doctors, nurse practitioners, physician assistants, pharmacists, and the managed care organizations (MCOs) that provide insurance coverage, such as hospitals, integrated delivery systems, pharmacy benefit managers, health plans, employers, and government agencies who hire MCOs to provide health benefits to their employees. The company also markets directly to consumers in the U.S. through direct-to-consumer advertising that communicates the approved uses, benefits, and risks of its products. For its infusion systems business, the company promotes directly to nurses, physicians, pharmacists, biomedical engineers, and their respective representatives. The company’s prescription pharmaceutical products are sold principally to wholesalers, and it also sells directly to retailers, hospitals, clinics, government agencies, and pharmacies; and in the case of vaccines products in the U.S., the company primarily sells directly to individual provider offices, the Centers for Disease Control and Prevention and wholesalers. The company’s global Consumer Healthcare business utilizes its own sales and marketing organizations to promote its produ
pfizer inc (PFE:SIX Swiss Exchange)
235 East 42nd Street
New York, NY 10017
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for PFE.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.